Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

UK NICE has recommended a scheme which would make bortezomib more accessible to UK NHS patients with multiple myeloma

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      National Institute for Health and Clinical Excellence.NICE recommends a scheme to make bortezomib (Velcade) for multiple myeloma accessible to NHS patients. Media Release: 4 Jun 2007. Available from: URL: http://www.nice.org.uk

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    UK NICE has recommended a scheme which would make bortezomib more accessible to UK NHS patients with multiple myeloma. Pharmacoecon. Outcomes News 530, 3 (2007). https://doi.org/10.2165/00151234-200705300-00008

    Download citation

    Keywords

    • Public Health
    • Health Outcome
    • Multiple Myeloma
    • Myeloma
    • Partial Response